ストックスクリーナーアプリを入手
6.87
3.62%
0.24
Helus Pharma Inc (HELP) 最新ニュース
HELP News Today | Why did Cybin stock go up today? $HELP - MarketBeat
H.C. Wainwright cuts Helus Pharma stock price target to $70 on dilution By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Helus Pharma stock price target to $70 on dilution - Investing.com Canada
HELP Stock Price, Quote & Chart - ChartMill
HELP Maintained by Canaccord Genuity -- Price Target Lowered to $42.00 - GuruFocus
Canaccord lowers Helus Pharma stock price target on valuation By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside - Stocktwits
Helus Pharma prices $50M public offering at $4.85 per share - MSN
Helus Pharma reports cash position and pipeline progress - grafa.com
HELPHelus Pharma Inc Latest SEC Filings - Finviz
Press Release: Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results - Moomoo
Cybin : MDA Q4 26 (Exhibit 99.3) Final - marketscreener.com
Helus Pharma reports Phase 3 trial progress, closes $50M offering - Investing.com Canada
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial ResultsMon, 06/29/202607:40 - Helus Pharma
Helus Pharma’s lead trial nears readout as cash hits $157.3M - Stock Titan
Cybin Inc. (HELP) Form 40-F: 51.63M shares, governance disclosures - Stock Titan
Cybin (HELP) As Phase 3 Enrollment Progresses, The Undervalued Narrative Holds - simplywall.st
Helus Pharma (HELP) Stock Analysis Report | Financials & Insights - Benzinga
Cybin: A Speculative Bet On Their Pivotal Depression Readout (NASDAQ:HELP) - Seeking Alpha
Helus Pharma's HLP003 Phase 3 results expected in Q4 2026, backed by strong funding and no debt. - Pluang
Cybin (HELP) Is Up 28.9% After Phase 3 HLP003 Progress And $50M Equity RaiseHas The Bull Case Changed? - Yahoo Finance
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year - Investing News Network
Cybin (HELP) Is Up 28.9% After HLP003 Phase 3 Enrollment Surpasses 86% in MDD Trial - simplywall.st
Helus Pharma™ Announces Closing of US$50 Million Underwritten OfferingThu, 06/25/202609:28 - Helus Pharma
Helus Pharma Raises US$50 Million to Advance Late-Stage Mental Health Drug Pipeline - TipRanks
Helus Pharma (Nasdaq: HELP) raises US$50M to fund NSA pipeline - Stock Titan
Helus Pharma raises US$50M to fund Phase 3 and anxiety programs - Stock Titan
Helus Pharma Prices US$50 Million Equity Offering to Advance Mental Health Drug Pipeline - TipRanks
Helus Pharma (HELP) prices US$50M share sale to fund Phase 3 MDD trial - Stock Titan
HELP Stock Price and Chart — NEO:HELP - TradingView
To Wall Street, psychedelics biotechs are more teammates than rivals - BioPharma Dive
Helus Pharma surpasses 86% enrollment in Phase 3 trial of HLP003 for depression - grafa.com
Cybin (HELP) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $HELP - MarketBeat
Helus Pharma™ Announces US$50 Million Underwritten OfferingWed, 06/24/202606:01 - Helus Pharma
Helus Pharma stock jumps on Phase 3 trial enrollment progress By Investing.com - Investing.com South Africa
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment ProgressWed, 06/24/202606:00 - Helus Pharma
Helus Pharma (HELP) Announces Successful Pricing of $50M Share O - GuruFocus
Helus Pharma (HELP) Reports Significant Progress in Clinical Tri - GuruFocus
Helus Pharma (HELP) Launches $50 Million Public Offering to Fund Clinical Pipeline - GuruFocus
Helus Pharma’s depression drug trial surpasses 86% enrollment - Investing.com UK
Helus Pharma’s depression drug trial surpasses 86% enrollment By Investing.com - Investing.com Australia
Helus Pharma Prices $50 Million Underwritten Offering - Moomoo
Helus Pharma prices $50 million stock offering at $4.85/share By Investing.com - Investing.com India
Helus Pharma Provides Update On Approach Phase 3 Trial Enrollment Progress - TradingView
Helus Pharma prices $50 million stock offering at $4.85/share - Investing.com
HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism - Stocktwits
2.64%
大文字化:
|
ボリューム (24 時間):